Sendai Virus Vector for iPS Cell Reprogramming

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current methods for generating induced pluripotent stem cells (iPS cells) face challenges such as random gene integration, chromosomal instability, and immunological rejection, which hinder their therapeutic application due to genetic differences from patient cells and the risk of tumorigenic transformation.

Innovation Solution

A Sendai virus vector system is used to reprogram human somatic cells with sustained expression of Oct3/4, Sox2, and Klf4 genes, ensuring genetic identity with the patient and preventing genomic integration, thereby enhancing safety and stability of the generated iPS cells.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If traditional viral vectors (retroviral, lentiviral, adenoviral) are used to generate iPS cells, then reprogramming can be achieved, but random gene integration occurs causing chromosomal instability and tumorigenic transformation

Engineering Contradiction:

Improvegenetic stabilityVSAvoidrandom gene integration

Core Design Contradiction:

ReliabilityVSObject-generated harmful factors

Solution Approach 1:

The patent employs Sendai virus as an intermediary vector system that delivers reprogramming genes without integrating into the host genome. The Sendai virus remains episomal in the cytoplasm, acting as a temporary mediator that provides sustained gene expression while avoiding genomic integration, thus resolving the contradiction between achieving reprogramming and preventing random gene integration

Inventive Principle:

Principle #24Intermediary (Mediator)

Solution Approach 2:

The patent extracts the harmful integration function from the viral vector system by using Sendai virus, which naturally does not integrate into host DNA. This extraction eliminates the source of chromosomal instability and tumorigenic transformation while maintaining the essential reprogramming function, thereby improving genetic stability

Inventive Principle:

Principle #2Taking out (Extraction)

2Adaptability or versatility

If embryonic stem cells or primordial germ cells are used as pluripotent stem cells, then self-renewal and differentiation potential are achieved, but genetic differences from patient cells cause immunological rejection

Engineering Contradiction:

ImprovepluripotencyVSAvoidgenetic compatibility

Core Design Contradiction:

Adaptability or versatilityVSReliability

Solution Approach 1:

The patent creates induced pluripotent stem cells by copying the genetic material of patient-specific somatic cells and reprogramming them to a pluripotent state. This copying process ensures that the resulting iPS cells have identical genetic sequences to the patient's cells, eliminating immunological rejection while maintaining pluripotency for therapeutic applications

Inventive Principle:

Principle #26Copying

3Duration of action of stationary object

If pluripotent stem cells are cultured extensively over long periods, then self-renewal is achieved, but chromosomal abnormalities appear reducing cell line homogeneity

Engineering Contradiction:

Improveself-renewal durationVSAvoidchromosomal stability

Core Design Contradiction:

Duration of action of stationary objectVSStability of the object's composition

Solution Approach 1:

The patent uses Sendai virus as a temporary, non-integrating vector that completes its function of delivering reprogramming genes and then disappears from the cell. This short-living vector approach avoids permanent genomic modification, allowing extensive cell culture and self-renewal without the chromosomal abnormalities that accumulate in long-term cultures of integrative vector-generated stem cells

Inventive Principle:

Principle #27Cheap short-living objects (Disposable)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

This approach achieves efficient generation of iPS cells that are genetically identical to the patient's cells, stable, and safe for therapeutic use, reducing the risk of immunological rejection and tumorigenic transformation, while maintaining high reproducibility and safety.

Implementation Method 1

A Sendai virus vector system is used to reprogram human somatic cells with sustained expression of Oct3/4, Sox2, and Klf4 genes

Methodology Applied

Scientific EffectViral transduction:

Implementation Method 2

ensuring genetic identity with the patient and preventing genomic integration, thereby enhancing safety and stability of the generated iPS cells

Methodology Applied

Scientific EffectEpisomal maintenance:

Data Source

PatentUS8496941B2Vectors for generating pluripotent stem cells and methods of producing pluripotent stem cells using the same

Publication Date: 2013.07.30 NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE & TECHNOLOGY

AI summary

Stem cell reprogramming genes cloned into a single sustained expression-type Sendai viral vector are shown to reprogram differentiated somatic cells into induced pluripotent stem (iPS) cells without integration of vector sequences into the host cell's genome. The genes are transduced into normal differentiated somatic cells via infection with recombinant Sendai virus. After expression of the reprogramming genes and subsequent induction of pluripotency, the vector genome RNA including the reprogramming genes is removed from the cell to establish an iPS cell that is genetically identical to the parent somatic differentiated cell thus reducing the risk of tumorigenic transformation caused by random integration of vector sequences into the host genome. The method promises to provide safe, autologous iPS cells that can be used for human cell replacement and regeneration therapeutic applications.